gba777 download free

SAN ANTONIO (AP) — Dylan Hayman scored 23 points as Incarnate Word beat Our Lady of the Lake 93-69 on Sunday night. Hayman also had five rebounds for the Cardinals (6-5). Davion Bailey shot 6 for 11 (6 for 10 from 3-point range) and 4 of 5 from the free-throw line to add 22 points. Harrison Reede had 14 points and shot 4 for 8 from beyond the arc and 2 of 3 from the free-throw line. Daniel Smith led the way for the Saints with 13 points. Our Lady of the Lake, a member of the NAIA, also got 11 points from Arthur Celestin. Tommie Law had 11 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

Before embarking on my today's writeup, full throttle, for preparatory warm up, dear readers, I mention four big names for those readers who have missed my previous four consecutive articles, under this very column. Following the tracks of a number of European travellers, like, the Frenchman Francis Bernier (1664-65); the British explorer Alexander Cunningham(1847); The Morovian missionary August Hermann Francke (1896) who travelled to Kashmir & Ladakh or for that matter Arthur Neve (-author of Tourist Guide to Kashmir, Ladakh and Skardu-1899) and the one that fascinates me nowadays- Edward Frederick Knight ( who toured Kashmir, Ladakh and Baltistaan in 1891) the expedition- lover- grand father of Michaela, namely Otto Honigmann visited Kashmir, Ladakh and Baltistaan in 1911-12. Here he clicked about 200 photographs that he, on returning home in May 1912, got mounted in a bound album. This is the treasure that Michaela's book offers to interested readers, like me. O n page 16 of this book she writes:“Hermann Francke- one of the best- known European Tibetologists, describes how during the building of the new bridge, in 1909, at Khalatse (khalsi)“....THE ANCIENT INDIAN INSCRIPTIONS IN 'KAROSHTHI' (and Brahmi) SCRIPT.... WERE ALMOST BLASTED....” From other sources we know some edicts of king Ashoka (272-231 BC) were in kharosthi Script; including the major Rock Edicts at Mansehra and Shahbazgarhi. [-Former is a city in Hazara; on Karakoram & The ancient Silk-route While the latter is in Mardan district...Both in Khyber Pakhtun Wala, (Pakistan-Afghanistan region); Once-Thriving- Buddhist Cities. Both. ] Hold on, dear readers! Experts say: 'THESE ROCK EDICTS APPEAR TO BE THE FIRST EXAMPLES OF WRITING IN SOUTH ASIA.' Kharosthi script? Wait, please ! First note,it. I prefer the romanized version of this word. Ghandhari, which appears on coins, inscriptions & Buddhist texts was the official language of the Kushan Empire; that was used by various people from North west of the Indian subcontinent i:e present Day Pakistan, Central Asia & Afghanistan. This Gandhari is also known as kharosthi Script. It is an early Middle Indo-Aryan language- a prakrit. Some experts of Linguistics have found evidence linking Ghandhari with the Dardic language and this Script was heavily used by the former Buddhist cultures of Central Asia & Eastern China. It is said The Birch-Bark Scrolls consisting of parts of the Dharma-Pada etc have been discovered in the recent past, in 1994 AD, in Eastern Afghanistan and Western Pakistan, in Hadda- west of Khyber Pass. Modern day experts claim that some manuscripts; including that of Mahayana Buddhism's Pure-Land-Sutras, that are in Kharosthi were brought from Gandhara to China as early AD 147AD AND the Kushan Monk, namely Lokaksema, used for translating it into Chinese. Experts say this Kharosthi Script was alive from 4th century BC to 3rd Century AD. One more interesting angle is the divergent Etymology of the word Qandahar/ Kandahar. We know it is a district of present day Afghanistan AND that it is believed to be 'one of the oldest known human settlements, according to some experts in the field History tells us during 6th Century BC it became an important outpost of the Achaemenid (Persian) Empire and in 4th Century BC, around 330 BC Alexander the great is said to have done much for its southern flank. We may also recall that Texila- that is 20 miles north of Islamabad (Pakistan), was also annexed by Alexander in, though Muriyas conquered it soon. In the local Pashto language the name Alexander is rendered as Iskander; that over a period of time is believed to have transformed to Kandahar/ Qandahar because of being a 'Tract Of Sweet Fruits' (like grapes, apricots etc). Kandahar enjoyed strategic location too; it being along the old trade routes of southern, central and Western Asia. Much later in time, as recent as around 1747 AD, the founder of Durrani dynasty, king Ahmed Shah Durrani, even made Qandahar the capital of his Afghan- empire. Other equally strong groups of exponents assert that etymologically the word Gandhara (of the script) transformed, with passage of time, to Kandahar/ Qandahar. Equally interesting is the claim of scholars who say the very word Kharosthi may have been derived from the Hebrew word Kharosheth, meaning writing. As per the English Archaeologist Sir John Marshall, [–1876-1958; who was Director General of the Archeological Survey 0f India from 1902 to 1928 AD, and who is known for his monumental work The Buddhist Art Of Gandhara ], kharosthi Script had relations with a form of Aramaic; that was used in the administrative work during the reign of Darius The Great (550 BC -486 BC); the Super-King whose great Achaemenid; empire(-of Iran) included much of Western Asia, Central Asia, The Indus valley, North-East Africa and even Greek Macedonia. Aramaic was the co-official language of this Achaemenid empire, along with Persian. Readers surely must be knowing that his religion/ faith is called Zoroastrianism (–Indo-Iranian-Religion);wherein Chief God is called Ahura Mazda (wise Lord); wherein figured concepts like Good & Evil as Light and Darkness, Reward etc but not Temples & Statues, just Fire-alter. Hope this much will suffice in today's column. More when health and time permits. Adieu. Poet/Penman/ Columnist, the author has been contributing non-political write-ups, from over two decades, to English Dailies of Kashmir, including Kashmir Observer Follow this link to join our WhatsApp group : Join Now Be Part of Quality Journalism Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. CLICK FOR DETAILS MENAFN30112024000215011059ID1108941996 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

FDA approves cancer drug developed by B.C.'s Zymeworks Cancer drug developed by Zymeworks in partnership with Jazz Pharmaceuticals Nelson Bennett Nov 21, 2024 3:45 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message B.C. biotech Zymeworks developed a drug discovery engine that has produced multiple candidates for treating cancers. Tyler Orton Listen to this article 00:02:29 The U.S. Food Drug Administration (FDA) has granted accelerated approval of a new drug for treating bilary tract cancer that was developed by Vancouver’ s Zymeworks Inc. (Nasdaq: ZYME) under a licensing and commercialization agreement with Jazz Pharmaceuticals. The new drug, Ziihera, could net Zymeworks more than $1 billion just in milestone payments, and millions more in royalties, upon full commercialization. Gaining the FDA’s accelerated approval triggers a $25 million milestone payment to Zymeworks from Jazz Pharmaceuticals – the first of more to come, should other milestones be reached. Under its licensing agreement, Zymeworks is eligible for up to $500 million in regulatory milestones, $862.5 million in commercial milestone payments, and royalties of 10 to 20 per cent on sales. “This approval represents the first FDA-approved therapy in Zymeworks’ pipeline, and validates the company’s novel Azymetric bispecific platform technology and internal research and development capabilities for novel multifunctional medicines,” Zymeworks says in a news release. “The FDA’s accelerated approval of Ziihera marks the culmination of more than a decade of research and development at Zymeworks, highlighting our deep scientific expertise in multifunctional biotherapeutics and unwavering commitment to innovation in drug development,” said Paul Moore, Zymeworks’ chief science officer. Ziihera is one of several variations of the bispecific antibody Zanidatamab that Zymeworks developed for treating various types of cancer, and one of three in the advanced “pivotal” trial phase. Several others are at phase 2 in clinical trials. In 2022, Zymeworks entered a licence and collaboration agreement with Jazz Pharmaceuticals Ireland Ltd -- a subsidiary of Jazz Pharmaceuticals plc -- for the exclusive development and commercialization rights to Zanidatamab in the U.S., Europe, Japan and other countries. A study published last year in The Lancet concluded that Zanidatamab “demonstrated meaningful clinical benefit with a manageable safety profile in patients with treatment-refractory, HER2-positive biliary tract cancer.” [email protected] twitter.com/nbennett_biv See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Get your daily Victoria news briefing Email Sign Up More Technology CRTC opens consultation on whether Big 3 telecoms can sell wholesale fibre internet Nov 21, 2024 2:05 PM How B.C.'s cleantech startups are cracking resource sector challenges Nov 20, 2024 4:00 PM Opinion: If TikTok poses a grave threat to national security, why are Canadians told they can keep using it? Nov 18, 2024 8:00 PM